Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

• Status: Terminated
• Trial end date: 2021-06-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prisma Health-Upstate
• Collaborator: Clemson University
• Treatments: Acetylcysteine; Famotidine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Age > 18

• performance of a SARS-CoV-2 test within 1 day of enrollment, N.B., must be positive to proceed to treatment phase of the trial

Exclusion Criteria:

• All patients under 18

• Known allergy to N-Acetyl Cysteine

• Known allergy to famotidine or other H2-receptor antagonists

• Pregnant or Nursing Mothers

• Laboratory Evidence or History of Renal Impairment (eGFR < 30 mL/min/1.73 m2)

• Taking H2-receptor antagonists, hydroxychloroquine or chloroquine.

• Patient has been admitted to the hospital prior to study enrollment